In this post-hoc analysis , we used prospectively collected data from tyrosine kinase inhibitor-naive patients with EGFR mutation-positive advanced ( stage IIIb-IV ) lung adenocarcinomas who were given afatinib in a single group phase @ trial ( LUX-Lung @ ) , and randomised phase @ trials ( LUX-Lung @ and LUX-Lung @ ) .